Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2007 2
2008 2
2009 5
2010 3
2011 2
2013 2
2014 4
2015 9
2016 7
2017 6
2018 6
2019 3
2020 3
2021 8
2022 8
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Yonezawa H, Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Yonezawa H, et al. Among authors: shinojima n. Neurooncol Adv. 2024 Apr 22;6(1):vdae037. doi: 10.1093/noajnl/vdae037. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38690230 Free PMC article.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Arakawa Y, et al. Among authors: shinojima n. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744697 Free PMC article.
Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N, Ozono K, Yamamoto H, Abe S, Sasaki R, Tomita Y, Kai A, Mori R, Yamamoto T, Uekawa K, Matsui H, Nosaka K, Matsuzaki H, Komohara Y, Mikami Y, Mukasa A. Shinojima N, et al. Brain Tumor Pathol. 2023 Jul;40(3):185-190. doi: 10.1007/s10014-023-00461-w. Epub 2023 Apr 22. Brain Tumor Pathol. 2023. PMID: 37086325 Free PMC article.
Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.
Yamashita S, Takeshima H, Hata N, Uchida H, Shinojima N, Yokogami K, Nakano Y, Sakata K, Fudaba H, Enomoto T, Nakahara Y, Ujifuku K, Sugawara K, Iwaki T, Sangatsuda Y, Yoshimoto K, Hanaya R, Mukasa A, Suzuki K, Yamamoto J, Negoto T, Nakamura H, Momii Y, Fujiki M, Abe H, Masuoka J, Abe T, Matsuo T, Ishiuchi S; Kyushu Neuro-Oncology Study Group. Yamashita S, et al. Among authors: shinojima n. J Neurooncol. 2023 Apr;162(2):425-433. doi: 10.1007/s11060-023-04310-w. Epub 2023 Apr 13. J Neurooncol. 2023. PMID: 37052748
Two children with lymphocytic hypophysitis presenting with positive anti-rabphilin-3A antibody.
Murai A, Shinojima N, Ikuta G, Ozono K, Ueda Y, Mabe H, Nakamura K, Iwata N, Fujisawa H, Nagamatsu F, Komatsu N, Uekawa K, Nishikawa S, Nakamura K, Mikami Y, Suzuki A, Sugimura Y, Mukasa A. Murai A, et al. Among authors: shinojima n. Endocr J. 2023 Jul 28;70(7):703-709. doi: 10.1507/endocrj.EJ22-0637. Epub 2023 May 13. Endocr J. 2023. PMID: 37045780 Free article.
83 results